Aktis Oncology Inc (NASDAQ: AKTS) is a clinical-stage oncology company developing targeted alpha therapy radiopharmaceuticals for cancer treatment. The company has no product revenue as of the 10-Q filed May 11, 2026, and funds operations through equity offerings, debt financings, and potential collaboration or licensing arrangements. Its lead candidate is [225Ac]Ac-AKY-1189, a radiopharmaceutical targeting Nectin-4 expressing tumors. Aktis has completed an initial public offering, the proceeds of which are reflected in its Q1 2026 financial statements. The company carries deferred revenue on its balance sheet, suggesting at least one collaboration or licensing agreement, though terms are not detailed in the available excerpts. With no committed sources of capital and no approved products, Aktis is pre-commercial and dependent on external financing to advance its pipeline.

Revenue model

Aktis generates no product revenue as of Q1 2026. It has deferred revenue on its balance sheet as of March 31, 2026 and December 31, 2025, indicating collaboration or licensing agreements. The company expects to finance operations through equity offerings, debt financings, collaborations, licenses, or other strategic arrangements.

Products and services

[225Ac]Ac-AKY-1189, a targeted alpha therapy radiopharmaceutical directed at Nectin-4 expressing tumors, is the lead product candidate in development as of the 10-Q filed May 11, 2026.

Customers and end markets

End market is oncology, specifically patients with Nectin-4 expressing tumors. No commercial customers as of Q1 2026. The company is pre-revenue from product sales.

Value-chain role

Clinical-stage drug developer. Aktis conducts research and development of radiopharmaceutical product candidates and plans to establish or contract for sales and marketing capabilities upon any future regulatory clearance.

Source: SEC 10-Q, filed 2026-05-11

Industry: Pharmaceutical Preparations